BioCryst Pharmaceuticals
BCRX
206 hedge funds and large institutions have $1.62B invested in BioCryst Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 74 increasing their positions, 55 reducing their positions, and 29 closing their positions.
101% more call options, than puts
Call options by funds: $77.9M | Put options by funds: $38.7M
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
35% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 55
31% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 29
10% more capital invested
Capital invested by funds: $1.48B → $1.62B (+$141M)
8.26% more ownership
Funds ownership: 57.74% → 66.01% (+8.3%)
5% more funds holding
Funds holding: 197 → 206 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$66.7M |
| 2 |
RM
RP Management
New York
|
+$50.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$36.7M |
| 4 |
BNP Paribas Asset Management
Paris,
France
|
+$25M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$20M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$19.5M |
| 2 |
Two Sigma Investments
New York
|
-$13.8M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$10.9M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$7.63M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$7.38M |
BCRX Hedge Fund Activity: Q4 2021 in Review
206 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q4 2021, worth a combined $1.62B — up 9.5% from $1.48B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new BCRX positions and 29 closed out — a net gain of 9 holders — while 74 added to existing stakes and 55 trimmed.
The largest buyer was Pictet Asset Management (Switzerland), adding an estimated $66.7M. The largest seller was HealthCor Management, cutting an estimated $19.5M.
- 206 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q4 2021, up from 197 in Q3 2021.
- Funds reported $1.62B of BioCryst Pharmaceuticals stock for Q4 2021, up 9.5% quarter-over-quarter.
- 38 funds opened new BioCryst Pharmaceuticals positions in Q4 2021 and 29 closed out, a net change of +9 holders.
- The largest BioCryst Pharmaceuticals buyer in Q4 2021 was Pictet Asset Management (Switzerland), an estimated $66.7M added.
- The largest BioCryst Pharmaceuticals seller in Q4 2021 was HealthCor Management, an estimated $19.5M sold.
Based on aggregated 13F filings for Q4 2021.